Insulin resistance in PCOS

Diagnosis and Management of Polycystic Ovary Syndrome

Volumn , Issue , 2009, Pages 35-61

  Diamanti Kandarakis, Evanthia ^a   Christakou, Charikleia D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891449555     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-09718-3_4     Document Type: Chapter

References (244)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
2. Poretsky L, Cataldo N, Rosenwaks Z, Giudice L. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535-82
3. Diamanti-Kandarakis E. and Papavasiliou A. Molecular mechanisms of insulin resistance in polycystic ovary syndrome Trends Mol Med 2006;12:324-32
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74
5. Dunaif A, Finegood DT. β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-47
6. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH, Raptis S. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44(4):525-31
7. Ducluzeau P, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, Pugeat M. Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome J Clin Endocrinol Metab 2003;88(8):3626-31
8. Fulgeshu A, Angioni S, Portoghese E, Milano F, Batetta B, Paoletti A, Melis G. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome Fertil Steril 2006;86:398-404.
9. Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, De Feo P, Orio F Jr. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92(8):3128-35
10. Healds A, Whitehead S, Anderson S, Cruickshank K, Riste L, Laing I, Rudenski A, Buckler H. Screening for insulin resistance in women with polycystic ovarian Syndrome Gyn Endocrinol 2005;20(2):84-91
11. Micic D, Sumarac-Dumanovic M, Kendereski A, Cvijovic G, Zoric S, Pejkovic D, Micic J, Milic N, Dieguez C, Casanueva F. Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome J Endocrinol Invest 2007;30:820-27
12. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome J Clin Endocrinol Metab 1998;83:2694-98
13. Jayagopal V, Kilpatrick ES, Holding PE, Jennings PE, Hepburn DA, Atkin SL. The biological variation of insulin resistance in polycystic ovarian syndrome J Clin Endocrinol Metab 2002;87:1560-62
14. Park KH, Kim JY, Ahn CW, Song YD, Lim SK, Lee HC. Polycystic ovarian syndrome (PCOS) and insulin resistance Int J Gynecol Obstetr 2001;74(3):261-67
15. De Paula Martins W, Santana LF, Nastri CO, Ferriani RA, De Sa MF, Dos Reis RM. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women Eur J Obstet Gynecol Reprod Biol 2007;133(2):203-7
16. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S and Gorska M Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome Hum Reprod 2007;22(7):1824-29
17. Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L. Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care 2002;25:1217-22
18. Ovesen P, Moller J, Ingerslev HJ, Jorgensen JO, Mengel A, Schmitz O, Alberti KG, Moller N. Normal basal and insulinstimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1993;77(6):1636-40
19. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K, Skrha J. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:2942-45
20. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A Heterogeneity in β-cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997;12:1897-1901
21. Gennarelli G, Rovei V, Novi R, Holte J, Bongioanni F, Revelli A, Pacini G, Cavallo-Perin P, Massobrio M. Preserved insulin sensitivity and β-cell activity, but decreased glucose effectiveness in normal-weight women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:3381-86
22. Vigil P, Contreras P, Alvarado J, Godoy A, Salgado A, Cortes M. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome Hum Reprod 2007;22:2974-80
23. Ciampelli M, Leoni F, Cucinelli F, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005;90:1398-406
24. Carmina E, Lobo R. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-65
25. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83(5):1454-60
26. Carmina E, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the finding of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metabol 2005;90:2545-49
27. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53(4):495-99
28. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15(6):1266-74
29. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome (Dunaif, A. et al., eds; Hershman, S. M., series ed.), Current Issues in Endocrinology and Metabolism, Blackwell Scientific Publications, Boston, 1992
30. The Rotterdam ESHRE ASRM-sponsored PCOS ConsensusWorkshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25
31. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Androgen Excess Society Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45
32. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovaries syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol 2007;67:735-42
33. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligoamenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66(4):513-17
34. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008;69(1):52-60
35. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13(6):251-57
36. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(1):162-8
37. Escobar-Morreale H, San Millan J. Abdominal adiposity and the polycystic ovary syndrome Trends in Endocrinol Metabol 2007;18(7):266-72
38. Lord J, Thomas R, Fox B, Acharya U, Wilkin T The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113(10):1203-9
39. Kahn S, Hull R, Utzschneider K. Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 2006;444(14):840-46
40. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome. Human Reprod 2003;11:2289-93
41. Vlassara H. Advanced glycation in health and disease: role of the modern environment Ann NY Acad Sci 2005;1043:452-60
42. Diamanti-Kandarakis E, Piperi C, Kalofoutis A and Creatsas G Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome Clin Endocrinol 2005;62:37-43
43. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, Panidis D. Increased serum Advanced Glycation End products is a distinct finding in lean women with PCOS. Clin Endocrinol (Oxf) 2008;69(4):634-41
44. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83(9):3078-82
45. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-49
46. Diamanti Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006;5:17-34
47. Sir Petermann T, Maliqueo M, Codner E, Echibur B, Crisosto N, Perez V, Perez-Bravo F, Cassorla F. Early metabolic derangements in daughters of women with PCOS J Clin Endocrin Metab 2007;92(12):4637-42
48. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005;11:631-43
49. Escobar-Morreale H, Luque-Ramirez M, San Millan J. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26 F: 251-82
50. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005;11(4):357-74
51. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75(1):53-8
52. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11
53. Ehrmann D, Kasza K, Azziz R, Legro R, Ghazzi M. Effects of Race and Family History of Type 2 Diabetes on Metabolic Status of Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2005;90(1):66-71
54. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002;45:959-64
55. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2031-36
56. Vrbíkov́a J, Grimmichov́a T, Dvoŕakov́a K, Hill M, Stanicḱa S, Vondra K. Family history of diabetes mellitus determines insulin sensitivity and beta cell function in polycystic ovary syndrome. Physiol Res 2008;57(4):547-53
57. Jackson S, Bagstaff S, Lynn S, Yeaman S, Turnbull D, Walker M. Decreased Insulin Responsiveness of Glucose Uptake in Cultured Human Skeletal Muscle Cells From Insulin-Resistant Nondiabetic Relatives of Type 2 Diabetic Families. Diabetes 2000;49:1169-77
58. Axelsen M, Smith U, Eriksson JW, Taskinen M-R, Jansson P-A. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 1999;131:27-31
59. Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G, et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 2005;20:2411-20.
60. Unlühizarci K, Özocak M, Tanriverdi F, Atmaca H and Kelestimur F. Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome Fertil Steril 2007;87:1377-82
61. Diamanti-Kandarakis E, Alexandraki K, Bergiele A. Presence of metabolic risk factors in non-obese PCOS sisters: Evidence of heritability of insulin resistance. J Endocrinol Invest. 2004;27:931-36
62. Dunaif A, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-10
63. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-31
64. Salley K, Wickham E, Cheang K, Essah P, Karjane N, Nestler J. Position statement: Glucose Intolerance in Polycystic Ovary Syndrome-A Position Statement of the Androgen Excess Society J Clin Endocrinol Metab 2007;92:4546-56
65. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonksy KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-27
66. Altuntas Y, Bilir M, Ucak S, Gundogdu S. Reactive hypoglycemia in lean young women with PCOS and correlations with insulin sensitivity and with beta cell function. Eur J Obstet Gynecol Reprod Biol. 2005;119:198-205
67. Samaras K, McElduff A, Twigg S, Proietto J, Prins J, Welborn T, Zimmet P, Chisholm D, Campbell L Insulin levels in insulin resistance: phantom of the metabolic opera? Med J Aust 2006;185(3):159-61
68. American Diabetes Association Consensus Development Conference on Insulin Resistance; 5-6 November 1997. Diabetes Care 1998;21:310-14
69. Cibula D, Skrha J, Hill M, Fanta M, Haakov́a L, Vrb Ikov́a J, Zivńy J. Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87(12):5821-25
70. Rabasa-Lhoret R, Bastard JP, Jan V, Ducluzeau PH, Andreelli F, Guebre F, Bruzeau J, Louche-Pellissier C, Ma Itrepierre C, Peyrat J, Chagńe J, Vidal H, Laville M. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. J Clin Endocrinol Metab 2003;88(10):4917-23
71. Skrha J, Haas T, Sindelka G, Pŕazńy M, Widimsḱy J, Cibula D, Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004;89(1):135-41
72. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:1273-76
73. Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, Campbell SE, Steffes MW. For the insulin standardization workgroup standardization of insulin immunoassays: report of the American Diabetes Association workgroup. Clinical Chemistry 2007;53:711-716
74. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23(3):295-301
75. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70
76. Cagnacci A, Arangino S, Renzi A, Cagnacci P, Volpe A. Insulin sensitivity in women: a comparison among values derived from intravenous glucose tolerance tests with different sampling frequency, oral glucose tolerance test or fasting Eur J Endocrinol 2001;145:281-87
77. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab 2001;86:4615-17
78. Abassi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 2002;51:235-37
79. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003;88(6):2534-40
80. Ehtisham S, Crabtree N, Clark P, Shaw N, Barrett T. Ethnic Differences in Insulin Resistance and Body Composition in United Kingdom Adolescents J Clin Endocrinol Metab 2005;90(7):3963-69
81. Whincup PH, Gilg JA, Papacosta O, Seymour C, Miller GJ, Alberti KG, Cook DG. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 2002;324:635
82. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol 2002;57:343-50
83. Kauffman VM, Baker P, Dimarino T, Gimpel VD. Castracane, Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations, Am J Obstet Gynecol 2002;187:1362-69
84. Dunaif A, Sorbara L, Delson R, Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 1993;42:1462-68
85. Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-90
86. Samoto T, Maruo T, Ladines-Llave CA, Matsuo H, Deguchi J, Barnea ER, Mochizuki M. Insulin receptor expression in follicular and stromal compartments of the human ovary over the course of follicular growth, regression and atresia. Endocr J 1993;40:715-26
87. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28(5):463-91
88. Mlinar B, Marc J, Janež A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007;375:20-35
89. Buchs A, Chagag P, Weiss M, Kish E, Levinson R, Aharoni D, Rapoport MJ. Normal p21Ras/MAP kinase pathway expression and function in PBMC from patients with polycystic ovary disease Int J Mol Med 2004;13:595-99
90. Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Yen SS, Olefsky JM. Lack of insulin resistance in fibroblasts from subjects with polycystic ovary syndrome. Metabolism 1998;47:940-46
91. Poretsky L. Commentary: polycystic ovary syndrome - increased or preserved ovarian sensitivity to insulin? J Clin Endocrinol Metab 2006;91:2859-60
92. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110-16
93. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56:295-308
94. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, Margara R, Hardy K, Franks S. Impaired insulindependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries Hum. Reprod 2005;20(2):373-81
95. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:E392-E399
96. Corbould A, Kim Y-B, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005;288:E1047-E1054
97. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006;55:751-59
98. Skov V, Glintborg D, Knudsen S, Jensen T, Kruse T, Tan Q, Brusgaard K, Beck-Nielsen H, Hojlund K. Reduced Expression of Nuclear-Encoded Genes Involved in Mitochondrial Oxidative Metabolism in Skeletal Muscle of Insulin-Resistant Women With Polycystic Ovary Syndrome. Diabetes 2007;56:2349-55
99. Orio F Jr, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L, Russo T, Tolino A, Lombardi G, Colao A, Vigorito C. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2967-71
100. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73
101. Ciaraldi TP, El-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:577-583
102. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-1266
103. Marsden PJ, Murdoch A, Taylor R Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome. Metabolism 1994;43(12):1536-42
104. Lystedt E, Westergren H, Brynhildsen J, Lindh-Astrand L, Gustavsson J, Nystrom F, Hammar M, Stralfors P. Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness. Eur J Endocrinol 2005;153:831-35
105. Mor E, Zograbyan A, Saadat P, Bayrak A, Tourgeman D, Zhang C, Stanczyk F, Paulson R. The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis Am J Obstet Gynecol 2004;190:1654-60
106. Goodarzi MO, Antoine HJ, Pall M, Cui J, Guo X, Azziz R. Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of the polycystic ovary syndrome Fertil Steril 2007;87:1473-76
107. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in PCOS: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993;264(2 Pt 1):E197-202
108. Seow KM, Juan CC, Hsu YP, Hwang JL, Huang LW, Ho LT. Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery Hum Reprod 2007;22(4):1003-10
109. Corton M, Botella-Carretero JI, Benguría A, Villuendas G, Zaballos A, San Milĺan JL, Escobar-Morreale HF, Peral B. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:328-337
110. Rosenfield R. Identifying Children at Risk for Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2007;92:787-96
111. Altuntas Y, Bilir M, Ozturk B. Comparison of various simple insulin sensitivity and β-cell function indices in lean hyperandrogenemic and normoandrogenemic young hirsute women. Fertil Steril 2003;80:133-42
112. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006;113:1148-1159.
113. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007;88:886-93
114. Codner E, Escobar-Morreale HF. Hyperandrogenism and Polycystic Ovary Syndrome (PCOS) in Women with Type 1 Diabetes Mellitus. J Clin Endocrin Metab 2007;92(4):1209-16
115. Huber-Buchholz MM, Carey D G P, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-74
116. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105-11
117. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome p450c17a activity and serum free testosterone after reduction ofinsulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23
118. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-74
119. Ryan CS, Nestler JE. Insulin-Sensitizing Drugs for the Treatment of Infertility in Polycystic Ovary Syndrome In Insulin resistance and polycystic ovarian syndrome: pathogenesis, evaluation and treatment. (Diamanti-Kandarakis, E. et al., eds), pp. 433-4747, Insulin Resistance and Polycystic Ovarian Syndrome: Edited by Evanthia Diamanti-Kandarakis, John Nestler, Dimitrios Panidis, Renato Pasquali Humana Press 2007
120. Ciotta L, Calogero AE, Farina M, De Leo V, La Marca A, Cianci A. Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod 2001;16:2066-72
121. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-24
122. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005;90:6099-105
123. Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001-5
124. Zhang G, Garmey JC, Veldhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17a-hydroxylase/17, 20-lyase (CYP17) genes in porcine theca cells. Endocrinology 2000;141:2735-42
125. Munir I, Yen HW, Geller DH, Torbati D, Bierden R, Weitsman S, Agarwal S, Magoffin D. Insulin augmentation of 17-α hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signa lregulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004;145:175-83
126. Carvalho C R O, Carvalheira JB, Lima MH, Zimmerman SF, Caperuto LC, Amanso A, Gasparetti AL, Meneghetti V, Zimmerman LF, Velloso LA et al. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 2003;144:38-47
127. Lima M, Souza L, Caperuto L, Bevilacqua E, Gasparetti A, Zanuto R, Saad M, Carvalho C. Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. J Endocrinol 2006;190:451-59
128. Garzo VG, Dorrington JH. Aromatase activity in human granulosa cells during follicular development and the modulation by follicle stimulating hormone and insulin. Am J Obstet Gynecol 1984;148:657-62
129. Greisen S, Ledet T, Ovesen P. Effects of androstenedione, insulin and LH on steroidogenesis in human granulosa luteal cells. Hum Reprod 2001;16:2061-65
130. McGee E, Sawetawan C, Bird I, Rainey WE, Carr BR. The effects of insulin on 3 b-hydroxysteroid dehydrogenase expression in human luteinized granulosa cells. J Soc Gynecol Investig 1995;2:535-41
131. Sekar N, Garmey JC, Veldhuis JD. Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory (stAR) protein and cytochrome P450 side-chain cleavage (P450scc) enzyme. Mol Cell Endocrinol 2000;159:25-35
132. Wu XK, Sallinen K, Anttila L, Makinen M, Luo C, Pollanen P, and Erkkola, R Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertil Steril 2000;74:564-72
133. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-78
134. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996;81:302-9
135. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91:22-4
136. Willis, D. Watson H, Mason H, Galea R, Brincat M, Franks S Premature response to LH of granulosa cells from anovulatory women with polycystic ovaries: relevance to mechanisms of anovulation. J Clin Endocrinol Metab 1998;83:3984-91
137. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001;86:1318-23
138. Dumesic DA, Schramm RD, Peterson E, Paprocki AM, Zhou R, Abbott DH. Impaired developmental competence of oocytes in adult prenatally androgenized female rhesus monkeys undergoing gonadotropin stimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:1111-19
139. Wu XK, Zhou SY, Liu JX, Pollanen P, Sallinen K, Makinen M, Erkkola R. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003;80:954-65
140. Phy J, Conover C, Abbot D, Zschunke M, Walker D, Session D, Tummon I, Thornhill A, Lesnick T, Dumesic D. Insulin and Messenger Ribonucleic Acid Expression of Insulin Receptor Isoforms in Ovarian Follicles from Nonhirsute Ovulatory Women and Polycystic Ovary Syndrome Patients J Clin Endocrinol Metab 2004;89:3561-66
141. Poretsky L, Seto-Young D, Shrestha A, S. Dhillon, Mirjany M, Liu HC, Yih M, Rosenwaks Z Phosphatidyl-inositol-3 kinaseindependent insulin action pathway (s) in the human ovary. J Clin Endocrinol Metab 2001;86:3115-9
142. Seto-Young D, Zajac J, Liu HC, Rosenwaks Z, Poretsky L. The role of mitogen-activated protein kinase in insulin and insulinlike growth factor I (IGF-I) signaling cascades for progesterone and IGF-binding protein-1 production in human granulosa cells. J Clin Endocrinol Metab 2003;88(7):3385-91
143. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ, Chang RJ. Enhanced granulosa cell responsiveness to folliclestimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;88:5624-31
144. Bhatia B, Price C. Insulin alters the effects of follicle stimulating hormone on aromatase in bovine granulosa cells in vitro. Steroids 2001;66:511-9
145. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intraovarian hyperandrogenism, may be the main culprit for the follicular arrest Hum Reprod Update 2004;10:107-17
146. Tarkun I, Arslan B, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592-96
147. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reproduction 2006;21(6):1426-31
148. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36(10):691-7
149. Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice A et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol 2000;52:487-92
150. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD, Sattar N. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87(7):3287-90
151. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G, Bersi C. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005;116:207-14
152. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666-73
153. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008;196(2):958-65
154. Orio Jr F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo R, Labella D, Zullo F, Lombardi G, Colao A Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome J Clin Endocrinol Metab 2004;89:4588-93
155. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742-46
156. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103(10):1410-5
157. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J and Mavrikakis M Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:749-756
158. Carmina E, Orio F, Palomba S, Longo RA, et al. Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. Am J Med 2006;119:356.e1-356.e6
159. Talbott E, Zborowski J, Rager J. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-61
160. Prelevic GM, Beljic T, Balint-Peric L, Ginsburg J. Cardiac flow velocity in women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995;43:677-81
161. Tiras MB, Yalcin R, Noyan V, Maral I, Yildirim M, Dortlemez O, Daya S. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 1999;14:1949-52
162. Orio F, Palomba S, Spinelli L, et al. The Cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-3701
163. Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, Uckan A, Kosar F. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 2007;22(11):2992-8
164. Cascella T, Palomba S, Tauchmanova L, Manguso F, Di Biase S, Labella D, Giallauria F, Vigorito C, Colao A, Lombardi G, Orio F Jr. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:4395-4400
165. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(2):576-80
166. Orio F, Palomba S, Cascella T, De Simone B, Manguso F, et al. Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-WeightWomen with Polycystic Ovary Syndrome: Results of a 6-Month Study. J Clin Endocrinol Metab 2005;90(11):6072-76
167. Diamanti-Kandarakis E. Pharmaceutical Intervention in Metabolic and Cardiovascular Risk Factors in Polycystic Ovary Syndrome. In Insulin resistance and polycystic ovarian syndrome: pathogenesis, evaluation and treatment (Diamanti-Kandarakis, E. et al., eds), pp. 367-387, Insulin Resistance and Polycystic Ovarian Syndrome: Edited by Evanthia Diamanti-Kandarakis, John Nestler, Dimitrios Panidis, Renato Pasquali: Humana Press 2007
168. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather thanmenstrual irregularity. J Clin Endocrinol Metab 2002;87:2128-33
169. Cagnacci A, Paoletti AM, Arangino S, Melis GB, Volpe A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod 1999;14:893-7
170. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-60
171. Polderman K, Gorren L, Asscheman H, Bakker A, Heine R. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-27
172. Elbers J, Giltay E, Teerlink T, Scheffer P, Asscheman H, Seidell J. Gooren LEffects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol 2003;58:562-571
173. Marsden PJ, Murdoch AP, Taylor R. Adipocyte insulin action following ovulation in polycystic ovarian syndrome. Hum Reprod 1999;14(9):2216-22
174. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007;192(3):585-94
175. Allemand MC, Asmann Y, Klaus K, Nair K. S An in vitro model for PCOS related insulin resistance: the effects of testosterone on phosphorylation of intracellular insulin signalling proteins in rat skeletal muscle primary culture. Fertil Steril Abstracts 2005;84(Suppl 1):S30-31
176. Mannerås L, Cajander S, Holm̈ang A, Seleskovic Z, Lystig T, L̈onn M, Stener Victorin E. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007;148(8):3781-91
177. Perello M, Castrogiovanni D, Giovambattista A, Gaillard RC, Spinedi E. Impairment in insulin sensitivity after early androgenization in the post-pubertal female rat. Life Sci 2007;80(19):1792-8
178. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51(9):2734-41
179. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003;18(9):1790-96
180. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS. Testosterone Selectively Reduces the High Molecular Weight Form of Adiponectin by Inhibiting Its Secretion from Adipocytes J Biol Chem 2005;280(18):18073-80
181. Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie 2005;87(1):39-43
182. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2699-2705
183. Perrini S, Natalicchio A, Laviola L, Belsanti G, Montrone C, Cignarelli A, Minielli V, Grano M, De Pergola G, Giorgino R, Giorgino F. Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 2004;53:41-52
184. Ishizuka T, Kajita K, Miura A, Ishikawa M, Kanoh Y, Itaya S, Kimura M, Muto N, Mune T, Morita H, Yasuda K. DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase. Am J Physiol 1999;276:E196-E204
185. Formoso G, Chen H, Kim J, Montagnani M, Consoli A, Quon M. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 2006;20:1153-63
186. Gonźalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006a; 91:336-340
187. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Botella-Carretero J, Villuendas G., Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806-11
188. Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006;29(3):419-23
189. Fencki V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease Fertil Steril 2003;80:123-27
190. Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diab Care 2008;31(2):328-34
191. Gonźalez F, Rote N, Minium J, Kirwan J. In vitro evidence that hyperglycemia stimulates TNF-α release in obese women with polycystic ovary syndrome. J Endocrinol 2006b; 188:521-29
192. Gonzalez F, Rote N, Minium J, Kirwan J. Increased activation of nuclear factor B triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006c; 91:1508-12
193. Naz RK, Thurston D, Santoro N. Circulating tumor necrosis factor (TNF)-a in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Am J Reprod Immunol 1995;34:170-75
194. Puder JJ, Varga S, Nusbaumer C P G, Zulewski H, Bilz S, M̈uller B, Keller U. Women with polycystic ovary syndrome are sensitive to the TNF-a lowering effect of glucose-induced hyperinsulinaemia. Eur J Clin Inves 2006;36:883-89
195. Wellen K, Hotamisligil G. Inflammation, stress, and diabetes. J Clin Invest 2005;115(5):1111-19
196. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini GB. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92:2500-5
197. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Fertil Steril 2003;79:1358-64
198. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014-21
199. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, Hermann AP. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006;155:337-45
200. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-47
201. Lumeng C, Deyoung S, Saltiel A. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007;292:E166-E174
202. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808
203. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031-H2041
204. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005;83:1708-16
205. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Human Reprod 2006;21(9):2257-65
206. Glintborg D, Frystyk J, Højlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol 2008;68(2):165-74
207. Sepilian V, Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Invest 2005;12:129-34
208. Aroda V, Ciaraldi T, Chang S, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 2008;89(5):1200-8
209. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 2004;27:528-34
210. Spranger J, M̈ohlig M, Wegewitz U, Ristow M, Pfeiffer A, Schill T, Schl̈osser H, Brabant G, Scḧofl C. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol 2004;61:738-46
211. Orio Jr F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2619-23
212. Shroff R, Kirschner A, Michelle M, Van Beek E, Jagasia D, Dokras A. Young ObeseWomen with Polycystic Ovary Syndrome have Evidence of Early Coronary Atherosclerosis. J Clin Endocrin Metab 2007;92(12):4609-14
213. Panidis D, Koliakos G, Kourtis A. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004;81:361-66
214. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007;88(2):401-5
215. Ost A, Danielsson A, Liden M, Eriksson U, Nystrom FH, Stralfors P. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J 2007;21(13):3696-704
216. Janke J, Engeli S, Boschmann M, Adams F, B̈ohnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805-10
217. Weiping L, Qingfeng C, Shikun M, Xiurong L, Hua Q, Xiaoshu B, Suhua Z, Qifu L. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006;30:283-88
218. Lee JW, Im JA, Lee DC. Retinol binding protein in non-obese women with polycystic ovary syndrome. Clin Endocrinol 2008;68:786-790
219. Hahn S, Backhaus M, Broecker-Preuss M, Tan S, Dietz T, Kimmig R, Schmidt M, Mann K, Janssen OE. Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. Eur J Endocrin 2007;157:201-207
220. Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care 2008;31(7):1427-32
221. Diamanti-Kandarakis E, Livadas S, Kandarakis S, Papassotiriou I and Margeli A. Low free plasma levels of Retinol-binding Protein 4 (RBP4) in insulin resistant subjects with Polycystic Ovary Syndrome. J Endocrinol Invest 2008, in Press.
222. Graham TE, Wason CJ, Bl̈uher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007;50(4):814-23
223. Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, Giudicelli J, Beguinot F, Van Obberghen E. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin eceptor substrate (IRS) signalling through a protein kinase C-α mediated mechanism. J Biol Chem 2003;278:47376-87
224. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007;30(10):2579-82
225. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, Papavassiliou AG, Duleba AJ. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581-89
226. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, Patsouris E, Papavassiliou AG. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med 2007;85(12):1413-20
227. Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, Tomer Y. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002;78:1240-43
228. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007;92(11):4191-98
229. Tucci S, Futterweit W, Concepcion ES, Greenberg DA, Villanueva R, Davies TF, Tomer Y. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001;86:446-49
230. Ukkola O, Rankinen T, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. A genome-wide linkage scan for steroids and SHBG levels in black and white families: the HERITAGE Family Study. J Clin Endocrinol Metab 2002;87:3708-20
231. El Mkadem SA, Lautier C, Macari F, Molinari N, Lefebvre P, Renard E, Gris JC, Cros G, Daures JP, Bringer J, White MF, Grigorescu F. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001;50:2164-68
232. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002a; 87:4297-4300
233. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995;9:284-92
234. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S, Conway GS, White D, Todd JA, Franks S et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997;349:986-90
235. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd, Spielman RS, Dunaif A. Thirtyseven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Nat Acad Sci USA 1999;96:8573-78
236. Calvo RM, Telleria D, Sancho J, San Millan JL, Escobar-Morreale HF. Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 2002;77:666-68.
237. Vankova M, Vrbikova J, Hill M, Cinek O, Bendlova B. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Ann N Y Acad Sci 2002;967:558-65
238. Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y, Imperial J, Bell GI, Cox NJ. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002b; 87:1669-73
239. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Royo JL, Real LM, Ruiz A. Comment: CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:3971-76
240. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Ruiz R, Fayez O, Galan JJ, Herreros JA et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003;88:5529-36
241. Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, Frayling TM, Wilkin TJ, Demaine A, Millward A et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:2606-10
242. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro (12) Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002;87:772-75
243. Witchel SF, White C, Siegel ME, Aston CE. Inconsistent effects of the proline12.alanine variant of the peroxisome proliferator-activated receptor-gamma2 gene on body mass index in children and adolescent girls. Fertil Steril 2001;76:741-47
244. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640-46